Abiomed

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.

preCARDIA is a provider of inpatient partially implantable devices for treating patients with acute decompensated heart failure.

Breethe, Inc. is a medical device company that focuses on developing wearable artificial lungs for both hospital and home use. Its flagship product, the OXY-1 System, is a portable external respiratory assistance device designed to facilitate blood circulation and gas exchange for patients experiencing acute respiratory or cardiopulmonary failure. This innovative technology allows for the removal of carbon dioxide and the addition of oxygen to the bloodstream, mimicking the function of a healthy lung. By eliminating the need for cumbersome oxygen tanks, the OXY-1 System enables patients requiring ECMO therapy to maintain greater mobility. Founded in 2014 and headquartered in Halethorpe, Maryland, Breethe operates as a subsidiary of Abiomed.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

Protembis GmbH, founded in 2017 and based in Aachen, Germany, specializes in manufacturing surgical equipment designed to enhance patient safety during transcatheter aortic valve replacement (TAVR) procedures. The company's ProtEmbo System addresses a significant complication associated with TAVR—cerebrovascular events—by utilizing an intra-aortic filter device that deflects potential embolic material away from the brain during the valve implantation process. As TAVR technology evolves and is increasingly performed on younger, lower-risk patients, Protembis aims to reduce the risk of adverse neurological outcomes, thereby improving overall patient care and outcomes in the treatment of valvular heart disease.

Protembis GmbH, founded in 2017 and based in Aachen, Germany, specializes in manufacturing surgical equipment designed to enhance patient safety during transcatheter aortic valve replacement (TAVR) procedures. The company's ProtEmbo System addresses a significant complication associated with TAVR—cerebrovascular events—by utilizing an intra-aortic filter device that deflects potential embolic material away from the brain during the valve implantation process. As TAVR technology evolves and is increasingly performed on younger, lower-risk patients, Protembis aims to reduce the risk of adverse neurological outcomes, thereby improving overall patient care and outcomes in the treatment of valvular heart disease.

RenalGuard Solutions, Inc. manufactures medical devices focused on cardiac and vascular markets, specifically aimed at preventing contrast-induced nephropathy (CIN) in at-risk patients undergoing imaging procedures. The company's primary product, RenalGuard, is designed to remove toxic contrast dyes from the kidneys and facilitate fluid balancing. It includes the RenalGuard Therapy, which helps mitigate the harmful effects of contrast media, and the RenalGuard System, comprising a console and a single-use set for infusion and urine collection. RenalGuard is already approved for sale in the European Union and has shown effectiveness in preventing CIN through various studies. The device is currently undergoing a pivotal trial in the United States for FDA approval. RenalGuard Solutions sells its products through a network of distributors domestically and internationally, and the company is headquartered in Milford, Massachusetts.

Reprieve Cardiovascular, Inc., a medical device company, develops and manufactures a medical fluid management device for congestive heart failure. It offers Reprieve technology, a fluid management therapy solution providing clinicians with the ability to precisely control a patient’s fluid volume for acute decompensated heart failure (ADHF) patients. The company was founded in 2018 and is based in Milford, Massachusetts. Reprieve Cardiovascular, Inc. operates as a subsidiary of CardioRenal Systems, Inc.

Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.

ECP Entwicklungsgesellschaft is a a medical device company and is developing a product that is a percutaneous, expandable catheter pump which increases blood circulation from the heart with an external drive shaft.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.